Personalis to Present at the Precision Breast Cancer Summit
17 6월 2020 - 2:00AM
Business Wire
Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics
for cancer, today announced the company’s participation at the
Precision: Breast Cancer Summit, which will be held online, June
16-17, 2020.
Personalis will present “Enabling multidimensional tumor
immunogenomics for advancing biomarker discovery,” featuring the
Personalis universal cancer immunogenomics platform, ImmunoID
NeXTTM. Christelle Johnson, PhD, will present for Personalis.
Dr. Johnson will discuss challenges facing immuno-oncology
translational and clinical researchers and review the importance of
insights into the complex and dynamic interactions between the
tumor and immune cells of the microenvironment. By combining highly
sensitive, exome-scale DNA and RNA sequencing with advanced
analytics, the ImmunoID NeXT Platform enables multidimensional
biomarker discovery utilizing a single sample preparation. This
presentation will feature a case study demonstrating the ability of
this immunogenomics profiling platform to uncover tumor escape
mechanisms and identify composite biomarkers of potentially greater
predictive capacity from patients treated with immune checkpoint
blockade.
About Personalis, Inc. Personalis, Inc. is a growing
cancer genomics company transforming the development of
next-generation therapies by providing more comprehensive molecular
data about each patient’s cancer and immune response. The
Personalis ImmunoID NeXT Platform™ is designed to adapt to the
complex and evolving understanding of cancer, providing its
biopharmaceutical customers with information on all of the
approximately 20,000 human genes, together with the immune system,
from a single tissue sample. Personalis also provides genomic
information to the VA Million Veterans Program as part of their
goal to sequence over a million veteran genomes. The Personalis
Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and
CAP-accredited. For more information, please visit
www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
Forward-Looking Statements This press release contains or
may imply "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements include
all statements that are not historical facts, including, for
example, statements regarding the future availability, features or
potential uses of the ImmunoID NeXT Platform and other future
events. These forward-looking statements are subject to risks and
uncertainties, including those related to the evolution of cancer
therapies and market adoption of our services, our expectations
regarding future performance, and the COVID-19 pandemic, as well as
other risks and uncertainties discussed in Personalis’ filings with
the Securities and Exchange Commission (SEC), including in the
“Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” sections of the
Company’s most recently filed periodic reports on Forms 10-K and
10-Q and subsequent filings and in the documents incorporated by
reference therein, all of which may significantly impact our
business and operations, the business and operations of our
customers, our ability to access capital and the value of our
common stock. Except as otherwise required by law, Personalis
disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date hereof,
whether as a result of new information, future events or
circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200616005866/en/
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024